Gasidblok-RD Capsule SR is a combination pharmaceutical formulation containing Domperidone 30 mg and Rabeprazole 20 mg, designed for the effective management of gastrointestinal disorders. Domperidone, a peripheral dopamine D2 receptor antagonist, facilitates gastric motility and accelerates gastric emptying, thereby alleviating symptoms such as nausea, vomiting, bloating, and gastric discomfort. Rabeprazole, a proton pump inhibitor (PPI), suppresses gastric acid secretion by irreversibly inhibiting the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells, promoting mucosal healing and providing symptomatic relief in acid-related conditions. The sustained-release (SR) formulation ensures prolonged therapeutic plasma concentrations, enhancing patient compliance and efficacy. Gasidblok-RD is indicated for the treatment of gastroesophageal reflux disease (GERD), peptic ulcer disease, and functional dyspepsia, particularly when accompanied by delayed gastric emptying or motility disturbances. It is also beneficial in managing symptoms associated with gastritis and Zollinger-Ellison syndrome. The combination therapy targets both acid suppression and motility enhancement, offering comprehensive symptom control. Caution is advised in patients with known hypersensitivity, cardiac arrhythmias, or hepatic impairment. Consultation with a healthcare professional is essential prior to initiation to ensure appropriate use and monitoring for potential adverse effects.

Dosage & How to Use